Key result
Potent P2Y12 inhibitors linked to ~18% lower mortality vs clopidogrel in ACS with CKD.
Why the study?
The safety and efficacy profiles of prasugrel and ticagrelor in real-life ACS patients with renal dysfunction needed to be established.
Do potent P2Y12 inhibitors (prasugrel and ticagrelor) reduce mortality and reinfarction compared to clopidogrel in ACS patients with chronic kidney disease?
Cohort (n=19,255)
Yes
Do potent P2Y12 inhibitors (prasugrel and ticagrelor) reduce mortality and reinfarction compared to clopidogrel in ACS patients with chronic kidney disease?
In a large real-world cohort of ACS patients with chronic kidney disease, use of potent P2Y12 inhibitors (prasugrel or ticagrelor) was associated with lower mortality and recurrent MI without an increased risk of major bleeding compared to clopidogrel.
Answers are grounded in this paper and cite their sources.
May support potent P2Y12 inhibitors in ACS with CKD; leaves open randomized confirmation of benefit.
AIMS: The aim of the present study was to establish the safety and efficacy profile of prasugrel and ticagrelor in real-life acute coronary syndrome (ACS) patients with renal dysfunction. METHODS AND RESULTS: All consecutive patients from RENAMI (REgistry of New Antiplatelets in patients with Myocardial Infarction) and BLEEMACS (Bleeding complications in a Multicenter registry of patients discharged with diagnosis of Acute Coronary Syndrome) registries were stratified according to estimated glomerular filtration rate (eGFR) lower or greater than 60 mL/min/1.73 m2. Death and myocardial infarction (MI) were the primary efficacy endpoints. Major bleedings (MBs), defined as Bleeding Academic Research Consortium bleeding types 3 to 5, constituted the safety endpoint. A total of 19 255 patients were enrolled. Mean age was 63 ± 12; 14 892 (77.3%) were males. A total of 2490 (12.9%) patients had chronic kidney disease (CKD), defined as eGFR <60 mL/min/1.73 m2. Mean follow-up was 13 ± 5 months. Mortality was significantly higher in CKD patients (9.4% vs. 2.6%, P < 0.0001), as well as the incidence of reinfarction (5.8% vs. 2.9%, P < 0.0001) and MB (5.7% vs. 3%, P < 0.0001). At Cox multivariable analysis, potent P2Y12 inhibitors significantly reduced the mortality rate [hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.54-0.96; P = 0.006] and the risk of reinfarction (HR 0.53, 95% CI 0.30-0.95; P = 0.033) in CKD patients as compared to clopidogrel. The reduction of risk of reinfarction was confirmed in patients with preserved renal function. Potent P2Y12 inhibitors did not increase the risk of MB in CKD patients (HR 1.00, 95% CI 0.59-1.68; P = 0.985). CONCLUSION: In ACS patients with CKD, prasugrel and ticagrelor are associated with lower risk of death and recurrent MI without increasing the risk of MB.
No takes yet. Share an insight, caveat, or question.
Filippo et al. (2019) conducted a cohort in Acute Coronary Syndrome with Chronic Kidney Disease (n=19,255). Potent P2Y12 inhibitors (prasugrel and ticagrelor) vs. Clopidogrel was evaluated on All-cause mortality in CKD patients (HR 0.82, 95% CI 0.54-0.96, p=0.006). In ACS patients with chronic kidney disease, potent P2Y12 inhibitors (prasugrel and ticagrelor) reduced the rate of mortality by 18% compared to clopidogrel.
Synapse has enriched 10 related papers. Consider them for comparative context: